Rift Valley Fever in Kenya

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-03-31

Study Completion Date

2006-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out how, why, and when Rift Valley Fever (RVF) spreads. Participants will be 250 adults and children, aged 1 year and older, from the Ijara District, Kenya. They will be given a questionnaire, undergo a medical examination that includes an eye exam, and have a 1-teaspoon sample of blood taken from a vein. Participation will take about 3 hours.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

RVF and Other Emerging Infectious Diseases in East and Central Africa

NCT05139524

Rift Valley Fever Hemorrhagic Fevers, Viral

RECRUITING

Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase

NCT00906880

Human African Trypanosomiasis

COMPLETED PHASE4

Plasmodium and Other Parasites in Pregnant Women and Children Around Margibi and Montserrado Counties, Liberia

NCT03719599

Malaria

COMPLETED

Prevalence of LF Infection in Districts Not Included in LF Control Activities

NCT03131401

Lymphatic Filariases Onchocerciasis

COMPLETED

Urinary Schistosomiasis Infection

NCT00138450

Diseases of the Urinary System Schistosomiasis Haematobia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this research is to better define the extent and timing of Rift Valley Fever (RVF) virus transmission and its related chronic disease/infection attack rate, during an interepidemic period in a high-risk region that has seen repeated RVF outbreaks. The results will be used to develop and refine predictive algorithms for RVF Virus transmission, based on epidemiological, environmental, and remote sensing data, with the ultimate goal of providing improved early detection of significant RVF outbreaks. It is expected that the analysis of test-performance characteristics will determine the best use of serologic assays in Kenya's next RVF epizootic/epidemic. The primary outcome measure will be the current RVF-specific seropositivity profile for a cross-sectional survey population in Ijara District in northeast Kenya. The secondary outcome measures to be studied will be: 1) an assessment of the behavioral factors associated with risk of seropositivity (previous infection) in the study population; and 2) the association of selected long-term ophthalmological and clinical outcomes with seropositivity. The study design for this protocol involves questionnaire administration to consenting participants of Ijara District, followed by performance of medical exams, ophthalmologic exams, and phlebotomy on all participants. ELISA testing for RVF will then be performed on the blood samples obtained, and all ELISA screen-positive samples will have confirmatory testing by plaque-reduction neutralizing antibody testing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rift Valley Fever

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Those adults and children residing in selected survey households in the area of Ijara Town and its 5 km environs who are 1 year of age and older will be eligible, provided:

1. Informed consent is obtained and signed, and assent form is obtained and signed from children age 7 and older,
2. Subject has understanding of study procedures, and
3. Subject is able to comply with study procedures for the entire length of the study.

Exclusion Criteria

1. Age less than 1 year.
2. Subjects who immigrated to the study area less than 2 years previously.
3. Acutely ill Ijara residents.
4. Adults and children who cannot provide informed consent or who cannot participate fully in the study procedures will also be excluded.

Minimum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes